Biomea Fusion
Biotechnology, 726 Main St, Downtown Redwood City, California, 94063, United States, 51-200 Employees
Phone Number: 16*********
Who is BIOMEA FUSION
We are a biopharmaceutical company focused on the discovery and development of covalent small molecules to treat patients with genetically defined cancers and metabolic diseases. A covale...
Read More
-
Headquarters: 726 Main St, Downtown Redwood City, California, 94063, United States
-
Date Founded: 2017
-
Employees: 51-200
-
Revenue: $10 Million to $25 Million
-
Active Tech Stack: See technologies
-
CEO:
Thomas Butler
Email
Phone
Industry: Biotechnology
SIC Code: 2834
Does something look wrong? Fix it. | View contact records from BIOMEA FUSION
Biomea Fusion Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Biomea Fusion
Answer: Biomea Fusion's headquarters are located at 726 Main St, Downtown Redwood City, California, 94063, United States
Answer: Biomea Fusion's phone number is 16*********
Answer: Biomea Fusion's official website is https://biomeafusion.com
Answer: Biomea Fusion's revenue is $10 Million to $25 Million
Answer: Biomea Fusion's SIC: 2834
Answer: Biomea Fusion has 51-200 employees
Answer: Biomea Fusion is in Biotechnology
Answer: Biomea Fusion contact info: Phone number: 16********* Website: https://biomeafusion.com
Answer: We are a biopharmaceutical company focused on the discovery and development of covalent small molecules to treat patients with genetically defined cancers and metabolic diseases. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein and offers a number of potential advantages over conventional non-covalent drugs including greater target selectivity, lower drug exposure and the ability to drive a deeper, more durable response. Leveraging our extensive expertise in covalent binding chemistry and development, we built our proprietary FUSIONTM System platform to advance a pipeline of novel covalent therapies. Our lead product candidate, BMF-219, is an orally bioavailable, potent and selective covalent inhibitor of MENIN, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. Beyond BMF-219, we are utilizing our novel platform to develop covalent treatments against other high-value oncogenic drivers of cancer. Our goal is to utilize our capabilities and platform to become a leader in developing covalent small molecules in order to maximize the depth and durability of clinical benefit when treating various cancers. The name biomea derives from the Greek word bios, meaning life, and the Latin word mea, meaning my. At Biomea Fusion, we develop medicines to improve the life of the individual.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Powered by
Sign in to CIENCE GO Data to uncover contact details
Free credits every month